




RESEARCH ARTICLE

# Needle lost in the haystack: multiple reaction monitoring fails to detect *Treponema pallidum* candidate protein biomarkers in plasma and urine samples from individuals with syphilis [version 1; referees: 1 approved, 1 approved with reservations]

Geert A. Van Raemdonck<sup>1,2\*</sup>, Kara K. Osbak <sup>1\*</sup>, Xaveer Van Ostade<sup>2\*</sup>, Chris R. Kenyon<sup>1,3\*</sup>

<sup>1</sup>HIV/STI Unit, Institute of Tropical Medicine, Antwerp, 2000, Belgium

<sup>2</sup>Laboratory for Protein Science, Proteomics and Epigenetic Signalling (PPES) and Centre for Proteomics (CFP), University of Antwerp, Wilrijk, 2610, Belgium

<sup>3</sup>Division of Infectious Diseases and HIV Medicine, University of Cape Town, Cape Town, 7925, South Africa

\* Equal contributors

**v1** **First published:** 19 Mar 2018, 7:336 (<https://doi.org/10.12688/f1000research.13964.1>)  
**Latest published:** 09 Oct 2018, 7:336 (<https://doi.org/10.12688/f1000research.13964.2>)

**Abstract**

**Background:** Current syphilis diagnostic strategies are lacking a sensitive manner of directly detecting *Treponema pallidum* antigens. A diagnostic test that could directly detect *T. pallidum* antigens in individuals with syphilis would be of considerable clinical utility, especially for the diagnosis of reinfections and for post-treatment serological follow-up.

**Methods:** In this study, 11 candidate *T. pallidum* biomarker proteins were chosen according to their physiochemical characteristics, *T. pallidum* specificity and predicted abundance. Thirty isotopically labelled proteotypic surrogate peptides (hPTPs) were synthesized and incorporated into a scheduled multiple reaction monitoring assay. Protein extracts from undepleted/unenriched plasma (N = 18) and urine (N = 4) samples from 18 individuals with syphilis in various clinical stages were tryptically digested, spiked with the hPTP mixture and analysed with a triple quadruple mass spectrometer.

**Results:** No endogenous PTPs corresponding to the eleven candidate biomarkers were detected in any samples analysed. To estimate the Limit of Detection (LOD) of a comparably sensitive mass spectrometer (LTQ-Orbitrap), two dilution series of rabbit cultured purified *T. pallidum* were prepared in PBS. Polyclonal anti-*T. pallidum* antibodies coupled to magnetic Dynabeads were used to enrich one sample series; no LOD improvement was found compared to the unenriched series. The estimated LOD of MS instruments is 300 *T. pallidum*/ml in PBS.

**Conclusions:** Biomarker protein detection likely failed due to the low (femtomoles/liter) predicted concentration of *T. pallidum* proteins. Alternative sample preparation strategies may improve the detectability of *T. pallidum* proteins in biofluids.

**Open Peer Review**

**Referee Status:** ? ✓

|  | Invited Referees |             |
|--|------------------|-------------|
|  | 1                | 2           |
| <b>REVISED</b>                               |                  |             |
| <b>version 2</b><br>published<br>09 Oct 2018 |                  |             |
| <b>version 1</b><br>published<br>19 Mar 2018 | ?<br>report      | ✓<br>report |

- 1 **Mohd M. Khan**, University of Maryland, USA
- 2 **Timothy Palzkill**, Baylor College of Medicine, USA

**Discuss this article**

Comments (0)

**Keywords**

MRM, Multiple Reaction Monitoring, targeted proteomics, *Treponema pallidum*, syphilis, biomarker discovery, antigen test, plasma

**Corresponding author:** Kara K. Osbak ([kosbak@hotmail.com](mailto:kosbak@hotmail.com))

**Author roles:** **Van Raemdonck GA:** Formal Analysis, Investigation, Methodology, Validation, Writing – Original Draft Preparation, Writing – Review & Editing; **Osbak KK:** Formal Analysis, Investigation, Methodology, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Van Ostade X:** Conceptualization, Project Administration, Resources, Supervision, Writing – Review & Editing; **Kenyon CR:** Conceptualization, Funding Acquisition, Investigation, Project Administration, Resources, Supervision, Writing – Review & Editing

**Competing interests:** No competing interests were disclosed.

**Grant information:** This work was supported by a grant from the Flanders Research Foundation, SOFI-B Grant (#757003) to CRK, <http://www.fwo.be/>.

*The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.*

**Copyright:** © 2018 Van Raemdonck GA *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution Licence](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**How to cite this article:** Van Raemdonck GA, Osbak KK, Van Ostade X and Kenyon CR. **Needle lost in the haystack: multiple reaction monitoring fails to detect *Treponema pallidum* candidate protein biomarkers in plasma and urine samples from individuals with syphilis [version 1; referees: 1 approved, 1 approved with reservations]** *F1000Research* 2018, 7:336 (<https://doi.org/10.12688/f1000research.13964.1>)

**First published:** 19 Mar 2018, 7:336 (<https://doi.org/10.12688/f1000research.13964.1>)

## List of abbreviations

|         |   |
|---------|---|
| hPTPs   | Isotopically labelled proteotypic surrogate peptides            |
| LOD     | Limit of detection  |
| MSM     | Men who have sex with men                                       |
| PCR     | Polymerase chain reaction                                       |
| TPPA    | Treponema pallidum Particle Agglutination test                  |
| RPR     | Rapid plasma reagin test  |
| COG     | Clusters of Orthologous Groups                                  |
| FA      | Formic acid   |
| PBS     | Phosphate buffered saline                                       |
| NSAF    | Normalized spectral abundance factor                            |
| IQR     | Interquartile range   |
| SISCAPA | Stable Isotope Standards and Capture by Anti-Peptide Antibodies |

## Introduction

*Treponema pallidum* ssp. *pallidum* (*T. pallidum*), a non-culturable microaerophilic spirochete, is responsible for more than 8 million new cases of syphilis per year<sup>1</sup>. There has been a resurgence of syphilis in a number of world regions over the last two decades<sup>1-3</sup>. In Europe<sup>2</sup> and North America<sup>3</sup>, this increase has been most marked in men who have sex with men (MSM). A striking feature of these outbreaks has been the increasing proportion of cases that are occurring in patients with a previous diagnosis of syphilis<sup>4,5</sup>. Patients with reinfections are more likely to present with asymptomatic or less symptomatic disease<sup>4</sup>, hence the diagnosis of reinfection is wholly dependent on subtle changes in serological tests<sup>6</sup>. Two types of serological tests are used to diagnose syphilis: treponemal tests detect antibodies to *T. pallidum* and non-treponemal tests, such as the Rapid plasma reagin (RPR) test, detect agglutination secondary to the presence of anti-lipoidal antibodies reactive to material released from damaged host cells and possibly cardiolipin released from *T. pallidum*<sup>7</sup>. Treponemal tests remain positive for life and are therefore of no use in the diagnosis of reinfection. Non-treponemal tests are used for syphilis post-treatment follow-up and diagnosis of reinfection. A wide range of factors can result in increases in test titers, causing syphilis to be over-diagnosed and unnecessarily treated<sup>6,8-10</sup>. Direct *T. pallidum* detection techniques, including various nucleic acid amplification tests, have been developed, but apart from testing of primary ulcer specimens the sensitivity of these techniques is low<sup>11</sup>. Even in the setting of secondary syphilis, when there is a high *T. pallidum* load in the blood<sup>12</sup>, the sensitivity of polymerase chain reaction (PCR) tests reaches only 52 % on serum specimens<sup>11,13</sup>.

The *T. pallidum* genome, through evolutionary reduction, is one of the smallest of the human bacterial pathogens, with a predicted 1044 open reading frames<sup>14</sup>. Approximately half of the predicted proteins have been detected through MS techniques<sup>15,16</sup>, including the semi-quantification of *T. pallidum* proteins using

spectral counting<sup>16</sup>. A *T. pallidum* transcriptome study demonstrated that almost all genes were expressed during peak rabbit experimental infection<sup>17</sup>. This maximum utilization of the genome, well characterized proteome, and swift invasion of the organism into the bloodstream (within 24 hours after infection<sup>18</sup>) make this pathogen an ideal candidate for antigen diagnostic assay development. A variety of antigen tests against other pathogens have been designed for clinical samples such as blood, cerebrospinal fluid, faeces and urine; and these have proven their utility in the diagnosis and assessment of therapeutic response in a number of infections, including *Helicobacter pylori*<sup>19</sup>, *Cryptococcus neoformans*<sup>20</sup>, *Cryptosporidium* ssp.<sup>21</sup>, *Entamoeba histolytica*<sup>22</sup>, Ebola virus<sup>23</sup> and *Mycobacteria tuberculosis*<sup>24</sup>. If a highly sensitive and specific test could be developed that is able to confirm the presence or absence of *T. pallidum* in the body then this would be of considerable utility in the diagnosis of syphilis reinfections and in assessing therapeutic response. It could also be useful for the diagnosis of neuro- and congenital syphilis – two diagnoses where contemporary tests are suboptimal<sup>25</sup>.

During the last decade, advanced MS-based proteomics platforms have emerged as mainstay bioanalytical tools for a broad range of clinical applications, including targeted protein identification<sup>26</sup> and bacteria identification and typing<sup>27</sup>. Particularly the AQUA workflow<sup>28,29</sup>, with its use of stable isotopically labelled standard proteotypic peptides (henceforth referred to as ‘heavy’ PTPs or hPTPs) and selected/multiple reaction monitoring-mass spectrometry (SRM/MRM MS), has emerged as a powerful technique for the fast determination of multiple protein concentrations in highly complex sample matrixes such as urine (reviewed by Mermelekas *et al.*<sup>30</sup>) and plasma (reviewed by Pernemalm and Lehtiö<sup>31</sup>). Precise quantitation of proteins is possible by using hPTPs as internal standards that correspond to endogenous peptides created during the enzymatic digestion of the sample of interest. When combined, the endogenous and synthetic peptides elute together chromatographically and ionize with the same efficiency. Since the quantity of the labelled peptide is known, the absolute quantity of the targeted native protein can be determined by comparing MRM hPTP/endogenous peak areas. The precision and utility of this highly sensitive multiplexed method has been demonstrated on undepleted/ unenriched plasma for the detection of a panel of human cardiovascular disease<sup>32</sup> and cancer<sup>33</sup> biomarkers with a detection capability of four orders of magnitude ( $10^3$ – $10^4$  range in protein concentration) and up to femtomolar level sensitivity in plasma<sup>34</sup>. Recently, a panel of 136 cancer candidate biomarkers was interrogated in unenriched urine samples using MRM, revealing detection limits of up to 25 picogram/ml urine<sup>35</sup>.

With regards to infectious disease biomarker studies, MS-based approaches identified candidate biomarkers in urine for *Leishmania* sp.<sup>36</sup>, which has led to the development of a urine capture ELISA diagnostic test<sup>37</sup>. Considerable progress has also been made in *Mycobacterium tuberculosis*<sup>38-40</sup> biomarker studies; recent advancements include the detection of *M. tuberculosis*

in urine using IgG capture, immunodepletion and MRM methods<sup>41</sup> and MRM assay of exosomes isolated from serum samples from patients with tuberculosis<sup>38</sup>.

In this study, we investigated if *T. pallidum* proteins could be detected in plasma and urine samples from individuals with syphilis using a targeted proteomics (MRM) approach. Successful development of a *T. pallidum* antigen test will most likely be contingent upon the simultaneous detection of multiple protein biomarkers to comprehensively cover different stages of disease. Eleven *T. pallidum* protein biomarkers were chosen based on a predicted specificity, high predicted abundance, and physicochemical properties. Thirty surrogate hPTPs were synthesized corresponding to eleven candidate *T. pallidum* biomarkers. Analysis of eighteen plasma and four urine samples revealed no detectable MRM signal for the endogenous peptides from the biomarkers of interest. This is likely due to the extremely low (femtomoles per liter) predicted concentration of bacterial proteins in the samples of interest, or the fact that the biomarkers are not expressed during infection. *T. pallidum* spiking experiments established a MS detection limit of 300 bacteria/ml in PBS; polyclonal anti-*T. pallidum* magnetic bead enrichment did not improve the protein detectability.

## Methods

### Study participants

Between January 2014 and August 2015, 120 patients attending the Institute of Tropical Medicine Antwerp clinic, over the age of 17 years, and in whom a new diagnosis of syphilis was made and had not received antibiotics in the preceding thirty days, were recruited into the cohort study. Thirty HIV-positive controls, in whom the diagnosis of syphilis was excluded via serological and PCR testing, were also recruited. The diagnosis and staging of syphilis was according to the Centers for Disease Control and Prevention classification<sup>42</sup>, and treatment was administered according to European guidelines<sup>43</sup>. All patient sera were tested for syphilis using a RPR test (BD Macro-Vue RPR card test, Becton, Dickinson and Co., Sparks, MD, United States of America (USA)) and an antibody detection *Treponema pallidum* Particle Agglutination test (SERODIA-TPPA Fujirebio Inc., Tokyo, Japan). A PCR test targeting *T. pallidum* *po1A* was also performed on serum<sup>44</sup> and whole blood samples were tested for multiple gene targets<sup>45</sup>, as previously described. Selection criteria of participants from the cohort study for the MRM assay analysis included a range of syphilis clinical stages and prioritized predicted high bacterial loads, as demonstrated by positive PCR tests and/or high RPR titres. Patients with early stage syphilis (primary, secondary, early latent) that were plasma and/or whole blood PCR positive for *T. pallidum* were expected to have the highest bacterial load<sup>11,12</sup>.

### Plasma and urine sample processing

Plasma was collected immediately before Benzathine Penicillin G intramuscular injection using 7.5 ml EDTA-coated blood collection tubes (Sarstedt Monovette, Nümbrecht, Germany). We refer to these samples as the *pre-penicillin* samples. A selection of randomly selected patients participated in an additional blood draw three hours after penicillin treatment since studies have shown penicillin to be fast acting on *T. pallidum*, leading to

consequent cell lysis and antigen release<sup>46</sup>. These samples are termed the *post-penicillin* samples. Plasma was chosen for the MRM assay according to HUPPO guidelines<sup>47</sup>. Protease inhibitors were not added to the plasma samples since previous studies did not demonstrate a significant higher protein yield with treated samples<sup>48</sup> and peptides could inadvertently be modified<sup>49</sup>. Plasma were subjected to dual centrifugation in an Eppendorf 22331 centrifuge (Hamburg, Germany) in an effort to minimize cellular contamination: whole blood was centrifuged at 2000 g for 10 minutes at ambient temperature, followed by transfer of the plasma fraction to a 50 ml falcon tube and centrifugation at 2400 g for 15 minutes. All plasma were processed and aliquoted into cryovials for storage at -80 °C in a long-term freezer unit (Eppendorf U725-G Innova New Brunswick, Hamburg, Germany) until further testing. Mid-stream random-void urine samples were collected and processed following HUPPO guidelines<sup>50</sup>, including centrifugation for 10 minutes at 2000 g at ambient temperature in order to remove insoluble contents such as cells and casts. Urine was aliquoted into 15 ml falcon tubes and stored at -80 °C until further testing. All plasma and urine samples were processed within three hours of collection and were only subjected to one freeze thaw cycle.

### *T. pallidum* protein biomarker selection

In a previous descriptive study we used non-gel based complementary MS techniques to characterize the proteome of *in vivo* rabbit cultured *T. pallidum*<sup>16</sup>. Candidate *T. pallidum* biomarker proteins for the MRM assay were chosen based on the following specific criteria: relative protein abundance (based on semi-quantitative spectral counting techniques<sup>16</sup>), Clusters of Orthologous Groups (COG) functional categorization, microarray transcriptome data<sup>17</sup>, protein size, physicochemical properties (i.e. previously detected by MS), predicted subcellular localization<sup>16</sup> and literature review. Each of the candidate biomarkers were digested *in silico* by subjecting the FASTA-formatted sequences to tryptic digestion, assuming 100 % digestion efficiency. Proteotypic peptides (PTPs) corresponding to these proteins were determined using ESPPredictor<sup>51</sup> and pBLAST<sup>52</sup>; analysis of the protein and PTPs was performed to determine possible homology with other bacterial species and human proteins. After PTP selection was finalized, isotopically labelled synthetic peptide standards (hPTPs) corresponding to the selected PTPs were synthesized (Heavy Peptide™ AQUA Basic with > 95 % purity; Thermo Fisher Scientific, Ulm, Germany).

### Plasma and urine sample preparation for MRM assay analysis

Protein concentrations of urine and plasma samples were determined based on the area under curve at 214 nm using a RP-C4 column (Vydac 214TP5415; 4.6×150 mm, particle size 5 µm; Alltech Associates Inc., Lokeren, Belgium) coupled to an Alliance e2695 HPLC system equipped with a 996 PDA detector (Waters Corporation, Milford, MA, USA). For each sample, 250 µg of protein was precipitated by adding six volumes of ice cold LC-MS grade acetone (Biosolve, Valkenswaard, the Netherlands) followed by overnight incubation in freezer unit (Liebherr, Bulle, Switzerland) at -20 °C. In all cases, lo-bind Eppendorf tubes (Eppendorf, Hamburg, Germany) were used to ensure high recovery rates of proteins and peptides. Protein pellets were

re-suspended in 50 mM Tris-HCl/6 M urea/5 mM dithiothreitol /10 % beta-mercaptoethanol (25  $\mu$ L/100  $\mu$ g protein) at pH 8.7. For the denaturation and reduction process all samples were incubated at 65 °C in a hot water bath for 1 hour. Subsequently, proteins in all fractions were diluted in 50 mM Tris-HCl/1 mM CaCl<sub>2</sub> (75  $\mu$ L/100  $\mu$ g protein) and alkylated by adding 200 mM iodoacetamide (10  $\mu$ L/100  $\mu$ g protein) during 1 hour at ambient temperature and protected from light. Proteomics-grade modified trypsin (Promega, Madison, WI, US) was added at a 30:1 protein-to-enzyme ratio. After incubation at 37 °C in a hot water bath for 18 hours the digestion was stopped by freezing the samples. Protein digests were desalted by SPE using GracePure SPE C18-Max (50 mg) (W. R. Grace & Co., Columbia, MD, US) RP cartridges and a vacuum manifold. SPE cartridges were conditioned with 100 % methanol and equilibrated with 100 % LC/MS grade H<sub>2</sub>O and 0.1 % formic acid (FA). After loading the complete acidified (0.1 % FA) tryptic digest, peptides were washed with 10 % methanol and eluted with 40 % methanol/ 40 % acetonitrile (ACN) and 0.1 % FA. Eluted peptides were lyophilized and frozen at -20 °C until further analysis. Immediately before analysis, lyophilized digests were resuspended in 5 % ACN/0.1 % FA and spiked with a mixture of all hPTPs.

#### MRM assay optimization and mass spectrometric analysis

Optimization of each PTP was performed on a triple quadrupole mass spectrometer (Waters Xevo TQ, Waters Corporation, Milford, MA, US) in order to obtain the most intense transitions. The capillary voltage was tuned to approximately 2 kV with a source temperature of 150 °C. Desolvation temperature was set at 400 °C with a nitrogen gas flow of 800 L/h. Cone voltage, collision energy and dwell times were optimized for each of the PTPs. All PTPs were dissolved in mobile phase A (MP-A), containing 5 % ACN (LC/MS grade) and 0.1 % FA. For each of the peptides individually, the Limit of Detection (LOD) was determined by performing a dilution series in MP-A. Based on these concentrations, a mixture of all hPTPs was made. A balanced hPTP mixture has been shown to increase quantification accuracy and reproducibility compared to an equimolar mixture in previous studies<sup>34</sup>. To check for possible suppressive effects of the plasma matrix, the hPTP mixture was spiked into plasma from a control study subject. A balanced mixture of hPTP (concentrations detailed in [Supplementary File 1](#)) was spiked into 50  $\mu$ g of plasma digest. Chromatographic separation of the plasma and urine samples was performed on a RP-C18 UPLC column (Waters, CSH 150  $\times$  2.1 mm, 1.7  $\mu$ m at 35 °C) connected to an Acquity UPLC system (Waters Corporation, Milford, MA, USA). In order to separate all peptides as best as possible, an optimized linear gradient of Mobile Phase B (MP-B) (0.1 % FA in 100 % ACN) was applied: 5 % MP-B during 1 min and from 5 to 35 % MP-B in 5 min, followed by a steep increase to 100 % MP-B in 1 min, all at a flow rate of 300  $\mu$ L/min. Based on the specific retention times of each peptide, three scheduled MRM runs of 10 minutes were generated, each of them containing 20 MS1 channels (10 endogenous (*T. pallidum*) PTPs without isotopic label and 10 channels with a synthetic hPTP equivalent). At least three transitions (ion pairs) were selected for each peptide of interest. For each scheduled MRM analysis, 50  $\mu$ g of peptides (injection loop of 5  $\mu$ L) per plasma/urine sample were loaded onto the analytical column. In

addition to an extensive needle wash after each injection, a blank run was performed between two subsequent clinical samples to prevent carry-over effects. Data acquisition was controlled by [MassLynx](#) version 4.1, while targeted datasets were analysed by [TargetLynx](#), which is part of [MassLynx](#) (Waters Corporation, Milford, MA, USA). All Xevo TQ MS raw spectral files are available at [PeptideAtlas](#)<sup>53</sup> with the identifier PASS00978.

#### Magnetic bead antibody-based enrichment of *T. pallidum* proteins and approximation of the MS LOD for *T. pallidum* protein detection

*T. pallidum* protein enrichment was performed using magnetic beads (Dynabeads® M-270, Life Technologies, CA, USA) coated with biotin-conjugated polyclonal *T. pallidum*-specific antibodies (PA1-73103, Thermo Fisher Scientific, CA, USA) through streptavidin-biotin conjugation. According to the manufacturer's protocol, 10  $\mu$ g of antibody was used to bind 1 mg of beads (approximately  $5 \times 10^7$  beads).

*In vivo* rabbit cultured purified *T. pallidum* DAL-1 strain extracts<sup>54,55</sup> were kindly provided by the group of David Šmajš from the Masaryk University, Czech Republic. The original concentration of the *T. pallidum* extract was approximately 10<sup>6</sup> bacteria/ml as quantified under darkfield microscopy using a Olympus BX41 (Olympus Corporation, Tokyo, Japan) equipped with darkfield microscope condenser DCW 1.4-1.2; magnification 10 $\times$ 40. Samples were stored in 1 ml phosphate buffered saline (PBS) and only subjected to one freeze-thaw cycle. Two dilution series of *T. pallidum* were prepared, each time starting in 1 ml of PBS and finally equating to eight approximate bacterial concentrations: 10<sup>4</sup>, 10<sup>3</sup>, 300, 100, 33, 10, 3 and 0 bacteria/ml.

For one dilution series, each of the eight fractions were incubated with a constant amount ( $\sim 10^5$ ) of magnetic beads coated with polyclonal anti-*T. pallidum* antibodies. After incubation for two hours at 4° C and magnetic separation, the supernatant was discarded and beads were washed three times with PBS. To lyse the antibody bound bacteria, 1 ml of PBS was added to each bead sample, these were sonicated on ice using a Sonics Vibra Cell VC130 (Sonics and Materials Inc., Newtown, CT, USA) (two times 30 seconds with an amplitude of 50 %). The bead fraction was retained (retentant) after sonication by using magnetic separation. Released proteins were precipitated adding ice-cold acetone and incubated overnight at -20 °C. Tryptic digestion was performed, following the aforementioned procedure, on both the precipitated proteins (supernatant) and directly "on-bead" (retentate), to test for possible unreleased proteins during sonication. For the second dilution series (unenriched), 1 ml was directly drawn from each of the eight samples. The samples from this series were also sonicated on ice (two times 30 seconds with an amplitude of 50 %) to lyse the bacteria. Released proteins were then acetone precipitated and subsequently digested, in conformance with the other parallel series procedure.

#### Liquid chromatography-electrospray ionization-LTQ-Orbitrap mass spectrometry analysis of enriched and non-enriched serially diluted *T. pallidum* samples

Peptide mixtures were separated by RPLC on a Waters nano-UPLC system using a nanoACQUITY BEH C18 Trap column (100 Å,

5  $\mu\text{m}$ , 180  $\mu\text{m} \times 20 \text{ mm}$ ) connected to a nanoACQUITY BEH C18 analytical Column (130  $\text{\AA}$ , 1.7  $\mu\text{m}$ , 100  $\mu\text{m} \times 100 \text{ mm}$ ) (Waters Corporation, Milford, MA, USA). Peptides were dissolved in MP-A, containing 2 % ACN and 0.1 % FA and spiked with 20 fmol [Glu1]-fibrinopeptide B, which serves as an internal calibrant. A linear gradient of MP-B (0.1 % FA in 98 % ACN) from 2 to 45 % MP-B in 45 min, followed by a steep increase to 95 % MP-B in 2 min at a flow rate of 400 nl/min. The nano-LC was coupled online with a LTQ Orbitrap Velos (Thermo Scientific, San Jose, CA, US) mass spectrometer using a PicoTip Emitter (New Objective, Woburn, MA, US) linked to a nanospray ion source. The mass spectrometer was set up in a data dependent acquisition MS/MS mode where a full scan spectrum (350–2500 m/z, resolution of 60.000) was followed by a maximum of ten CID tandem mass spectra (100 to 2000 m/z). Peptide ions were selected as the twenty most intense peaks of the MS scan. CID scans were acquired in the LTQ ion trap part of the mass spectrometer with normalized collision energy of 32 %.

Obtained spectra were screened against the *T. pallidum* reference and resequenced databases (UniProt ID proteome UP000014259<sup>14</sup> and UP000000811<sup>56</sup> using the MASCOT search engine

(Matrix Science; version 2.1.03) based on the digestion enzyme trypsin. Carbamidomethylation of cysteines was listed as a fixed modification, while methionine oxidation was set as a variable modification. A maximum of one missed cleavage was tolerated. Mass tolerance was set to 10 ppm for the precursors and 0.8 Da for the fragment ions. False discovery rate was set at 5 %. Scaffold Q+ (version 4.6.2, Proteome Software Inc., Portland, OR, US) was used to validate MS/MS-based peptide and protein identifications. Protein identifications were accepted if they could be established at greater than 95.0 % probability according to the protein prophet algorithm<sup>57</sup>.

All LTQ-Orbitrap MS/MS raw spectral data is available at PeptideAtlas<sup>53</sup> with the identifier PASS00978.

## Results

### Study subject inclusion

Eighteen syphilis-infected study participants were selected for the MRM assay analyses (Table 1). All participants were male and identified as MSM. A third of the participants (6/18; 33 %) were HIV positive. Five (28 %) presented with primary, eleven secondary (61 %), and two early latent (11 %) stage disease.

**Table 1. Summary of the clinical and laboratory characteristics of study subjects included in this study.**

| Patient Number | HIV status | Syphilis stage | Sample type | Pre or post-treatment sampling <sup>#</sup> | PCR Whole Blood | PCR Serum | RPR titre | TPPA titre |
|----------------|------------|----------------|-------------|---|-----------------|-----------|-----------|------------|
| 1              | Positive   | Secondary      | Plasma      | Pre   | Positive        | Indet.    | 1/512     | >1/20480   |
| 2              | Negative   | Primary        | Plasma      | Pre   | Negative        | Indet.    | 1/4       | 1/160      |
| 3              | Positive   | Early latent   | Plasma      | Pre   | Negative        | Positive  | 1/1       | 1/1280     |
| 4              | Positive   | Secondary      | Plasma      | Pre   | Positive        | Positive  | 1/128     | 1/20480    |
| 5              | Positive   | Secondary      | Plasma      | Pre   | Positive        | Positive  | 1/128     | >1/20480   |
| 6              | Negative   | Secondary      | Plasma      | Pre   | Negative        | Positive  | 1/128     | >1/20480   |
| 7              | Positive   | Early Latent   | Plasma      | Pre   | Positive        | Positive  | 1/64      | 1/10240    |
| 8              | Positive   | Secondary      | Plasma      | Pre   | Positive        | Indet.    | 1/32      | 1/1280     |
| 9              | Positive   | Secondary      | Plasma      | Pre   | Positive        | Positive  | 1/512     | >1/20480   |
|                |            |                | Urine       |   |                 |           |           |            |
| 10             | Negative   | Primary        | Plasma      | Pre   | Positive        | Indet.    | 1/16      | 1/5120     |
|                |            |                | Urine       |   |                 |           |           |            |
| 11             | Positive   | Secondary      | Plasma      | Pre   | ND              | Indet.    | 1/128     | >1/20480   |
| 12             | Negative   | Secondary      | Plasma      | Pre   | Positive        | Negative  | 1/32      | >1/20480   |
| 13             | Positive   | Secondary      | Plasma      | Post  | ND              | Indet.    | 1/128     | >1/20480   |
| 14             | Negative   | Primary        | Plasma      | Post  | Positive        | Indet.    | 1/16      | 1/5120     |
|                |            |                | Urine       |   |                 |           |           |            |
| 15             | Negative   | Primary        | Plasma      | Post  | Negative        | Indet.    | 1/8       | 1/1280     |
| 16             | Positive   | Secondary      | Plasma      | Post  | Positive        | Negative  | 1/64      | 1/20480    |
| 17             | Positive   | Primary        | Plasma      | Post  | Positive        | Negative  | 1/64      | >1/20480   |
| 18             | Positive   | Secondary      | Plasma      | Post  | Negative        | Negative  | 1/128     | >1/20480   |

Legend: <sup>#</sup>- patients were treated with intramuscular injection with 2.4 MU Benzathine penicillin G; Indet.- indeterminate PCR result, second confirmatory PCR was not performed; ND- not done

Thirteen participants were confirmed *T. pallidum*-positive by serum and/or whole blood PCR testing. Four participants had indeterminate PCR results, meaning their sample was weakly positive. A second confirmatory PCR was not performed on these samples. One patient was negative for both whole blood and serum PCR. All participants tested positive with both the RPR and TPPA tests. The median RPR value was 1/64 (Interquartile range (IQR): 1/16- 1/128). In total, 22 samples were analysed, including N = 12 pre-penicillin treatment plasma, N = 6 post-penicillin treatment plasma and N = 4 pre-penicillin treatment urine samples.

### *T. pallidum* protein biomarker selection

Eleven *T. pallidum* proteins were selected as candidate biomarkers (Table 2). Most selected biomarkers had high normalized spectral abundance factor (NSAF) scores according to our previous study<sup>16</sup> (median 4.02; IQR: 1.97-6.97) and high microarray signal ratios<sup>17</sup> (median 3.05; IQR: 0.74-6.8). The median protein molecular weight was 39 kDa (IQR: 28-81). Two proteins were predicted to be located in the flagellum (TP\_0249 and TP\_0792), two in the ribosome (TP\_0250b and TP\_0244) and the subcellular localization of five proteins was unknown. Protein TP\_0326, a BamA orthologue, has been experimentally shown<sup>58-60</sup> to be localized in the outer membrane. A typical target for PCR assays is *poIA*, coding protein TP\_0105<sup>61</sup>. One protein, Peptidyl-prolyl cis-trans isomerase (TP\_0862) was found in a previous proteomics study where it demonstrated moderate reactivity during immunoblot experiments with human and rabbit *T. pallidum* infected serum<sup>15</sup>. Protein TprG (TP\_0317) is part of the paralogous *tpr* gene family that encodes candidate virulence factors<sup>62</sup> and is partially homologous to Tpr E/J. According to pBLAST analysis, all chosen biomarker proteins and corresponding PTPs did not demonstrate high homology with other pathogens, non-pathogenic commensal bacterial or human proteins (data not shown). One to three corresponding well-suited PTPs were selected for each biomarker, for a total of 30 PTPs. Details pertaining to these are provided in Table 2.

### Multiple reaction monitoring assay optimization

The LOD for each peptide was determined individually by performing a dilution series of MP-A whereby the median LOD was 68.5 (IQR 14.2-176.7) picomoles. Once the peptide mixture composition was optimized based on the LOD, 2  $\mu$ L of this mixture (Supplementary File 1) was spiked into 50  $\mu$ g plasma from a control patient whereby no significant variations in the signal of the hPTP transitions could be detected, indicating that there was no evidence of transition interference from the plasma. After optimizing each of the PTPs, three different sets of transitions were combined in an MRM assay based on their chromatographic retention time, as detailed in Supplementary File 1. The experiments contained a total of 141 targeted ion pairs (transitions) corresponding to 30 PTPs from eleven *T. pallidum* proteins. Ten of the eleven proteins were represented by two or more (h)PTPs (Table 2/ Supplementary File 1). In total, three scheduled MRM assays of 10 minutes, each containing 20 peptides (10 endogenous (*T. pallidum*) peptides and 10 hPTP standards) were developed. These assays were evaluated based on a balanced mixture of all 30 hPTPs standards. Unfortunately, although each of the 30 spiked hPTPs could be detected, none of the

selected endogenous *T. pallidum* peptides could be identified in any of the MRM assays (Figure 1; Supplementary File 2\*).

### Estimation of mass spectrometry LOD and ineffective *T. pallidum* protein enrichment using magnetic bead coupled polyclonal anti-*T. pallidum* antibodies

Two *T. pallidum* spiking dilution series were prepared in PBS and subjected to LTQ-Orbitrap MS/MS analysis in order to estimate the LOD of MS detection. One of the series was subjected to an additional polyclonal antibody coupled magnetic bead enrichment step, including sonication of the beads and subsequent separate measurement of the lysate and on-bead digestion retentate (Figure 2).


Two unique *T. pallidum* proteins, Cytoplasmic filament protein A (TP\_0748) and Lipoprotein antigen Tp47 (TP\_0547), were found in the 300 bacteria/ml fraction in the enriched and unenriched samples, respectively (Figure 3; Supplementary File 3). Therefore, the LOD based on a high-resolution LTQ-Orbitrap instrument was approximately 300 bacteria/ml PBS for both the antibody enriched and unenriched samples, meaning there was no significant improvement in LOD using bead enrichment. No proteins were detected in any sample concentrations for the enriched bacterial lysate (supernatant) fraction. Possibly, the sonication conditions were not harsh enough to lyse the bacteria on the beads and lysis was mainly the results of trypsin treatment under denaturing conditions. In total, eight unique *T. pallidum* proteins were found in both the unenriched and enriched retentate dilution series: 60 kDa chaperonin (TP\_0030), Flagellar filament outer layer protein flaA1 (TP\_0249), Alkyl hydroperoxide reductase (TP\_0509), Lipoprotein antigen Tp47 (TP\_0574), Galactose ABC superfamily ATP binding cassette transporter, binding protein (TP\_0684), Cytoplasmic filament protein A (TP\_0748) and the Flagellar filament core proteins flaB1/B3 (TP\_0792/TP\_0870). Four proteins, Lipoprotein, 15 kDa (TP\_0171), 10 kDa chaperonin (TP\_1013), Elongation factor Tu (TP\_0187) and Tp34 lipoprotein (TP\_0971) were only found in the unenriched and enriched series, respectively. Ten unique *T. pallidum* proteins were found in the highest concentration ( $10^4$  bacteria/ml) for both the enriched retentate sample (N = 10) and non-enriched sample (N = 10). Five unique *T. pallidum* proteins were found in the  $10^3$  bacteria/ml sample, including N = 4 in the unenriched and N = 4 in the retentate fractions. A peptide (LSGGVAVIK) related to 60 kDa chaperonin (TP\_0030) was detected in the low concentration (100/ 33/ 10/ 3 bacteria/ml) and in the negative control samples of the enriched sample series. This was likely a false-positive non-specific peptide secondary to rabbit protein contamination since this short peptide sequence is closely homologous to the *Oryctolagus cuniculus* (rabbit) 60 kDa heat shock protein, or could have originated from the beads or antibodies. As a result, it has been excluded from the analysis. Three *T. pallidum* proteins detected in both the enriched and unenriched sample series were also biomarker candidates tested in the MRM assay experiments: Flagellar filament core protein flaB2 (TP\_0792), Cytoplasmic filament protein A (TP\_0748) and the Flagellar filament outer layer protein flaA1 (TP\_0249). Detailed information about the identified proteins, peptides, coverage and search parameters can be found in Supplementary File 3. Rough

**Table 2. List of *T. pallidum* protein biomarker candidates and their corresponding proteotypic peptides (PTPs).**


| Number | UniProt Accession Number* | TP Number/ gene             | Protein Name  | Peptide Number | Peptide Sequence#             | Protein Weight (kDa) | Predicted Subcellular Location <sup>8</sup> | COG category function | Spectral Count NSAFF value in <i>T. pallidum</i> <sup>16</sup> | cDNA/ DNA signal ratio <sup>17</sup> |
|--------|---------------------------|-----------------------------|---|----------------|-------------------------------|----------------------|---|-----------------------|--|--------------------------------------|
| 1      | R9US76                    | TP_0105/ <i>poIA</i>        | DNA-directed DNA polymerase   | 16             | TSAVSGAIPENR                  |                      |   |                       |  |                                      |
|        |                           |                             |   | 17             | MALNTQIQSSAADIVK              |                      |   |                       |  |                                      |
|        |                           |                             |   | 18             | VHTSFVQIGTATGR                | 112                  | NK  | L                     | 2.55   | 0.283                                |
| 2      | O83346                    | TP_0326/ <i>tp92</i>        | Putative outer membrane protein assembly factor   | 19             | TEAGGVVVGFTIQEGK              |                      |   |                       |  |                                      |
|        |                           |                             |   | 20             | EQWASSPGLAESER                |                      |   |                       |  |                                      |
|        |                           |                             |   | 21             | LAFANITFTSPGGIPK              | 94                   | Outer Membrane                              | M                     | 1.77   | 0.682                                |
| 3      | R9UVD9                    | TP_0249/ <i>flaA1</i>       | Flagellar filament outer layer protein  | 22             | LATEVGFPSGGAAQR               |                      |   |                       |  |                                      |
|        |                           |                             |   | 23             | DESVLIDFAK                    | 39                   | NK  | N                     | 7.47   | 16.05                                |
|        |                           |                             |   | 24             | GTLLDGTVFDASR                 |                      |   |                       |  |                                      |
|        |                           |                             |   | 25             | KPGVQVTSSGLQYEVVK             |                      |   |                       |  |                                      |
| 4      | O83834                    | TP_0862/ <i>fkIB</i>        | Peptidyl-prolyl cis-trans isomerase   | 27             | FYVPSLGYGER                   | 28                   | NK  | O                     | NF   | 5.29                                 |
|        |                           |                             |   | 26             | MPPSPCAVLR                    |                      |   |                       |  |                                      |
|        |                           |                             |   | 30             | VASVVVSVDNRR                  |                      |   |                       |  |                                      |
| 5      | O83892 <sup>8</sup>       | TP_0922                     | Uncharacterized Protein   | 28             | YFLPGECAQR                    | 33                   | NK  | None                  | 7.80   | 1.599                                |
| 6      | R9USJ3                    | TP_0250b/ <i>rpsT</i>       | 30S ribosomal protein S20   | 29             | LYNGVFSSPEVVR                 | 11                   | Ribosome                                    | None                  | 5.28   | 3.39                                 |
|        |                           |                             |   | 10             | TGEEPLPVTK                    |                      |   |                       |  |                                      |
|        |                           |                             |   | 9              | ATAVGIMYDCLER                 |                      |   |                       |  |                                      |
| 7      | R9UU30                    | TP_0244/ <i>rpsG</i>        | 30S ribosomal protein S7  | 11             | LAAEILDAYHSTGTAFK             | 18                   | Ribosome                                    | J                     | 6.78   | 3.053                                |
|        |                           |                             |   | 1              | VLDAVTAATEETALQSR             |                      |   |                       |  |                                      |
|        |                           |                             |   | 8              | GNPMSLFLNLPDQQK               |                      |   |                       |  |                                      |
| 8      | O83337                    | TP_0317                     | Tpr protein G   | 2              | LTGSATLEWGISYGGK <sup>8</sup> | 81                   | NK  | None                  | 1.32   | 0.743                                |
|        |                           |                             |   | 6              | ELSVQAANGIYSAEDR              |                      |   |                       |  |                                      |
|        |                           |                             |   | 7              | DAGDESVMNIDSPEK               |                      |   |                       |  |                                      |
| 9      | P21991                    | TP_0792/ <i>flaB1</i>       | Flagellar filament core protein FlaB  | 12             | AYIGTMTAVAMGIR                | 31                   | Flagellum                                   | N                     | 6.97   | 13.82                                |
|        |                           |                             |   | 3              | GVNELETHINSLLR                |                      |   |                       |  |                                      |
|        |                           |                             |   | 4              | ADIGQSFASDGSADQK              |                      |   |                       |  |                                      |
| 10     | R9UTS8                    | TP_0748/ <i>cfpA/ tpn83</i> | Cytoplasmic filament protein A  | 5              | EYDDTDSINLPDER                | 79                   | Cytoplasm                                   | S                     | 2.75   | 6.79                                 |
|        |                           |                             |   | 13             | EIGLASGELPA <sup>14</sup> TR  |                      |   |                       |  |                                      |
|        |                           |                             |   | 14             | SVVVSATDESPLAR                |                      |   |                       |  |                                      |
| 11     | O83417                    | TP_0402/ <i>flil</i>        | IIIISP family Type III (Virulence-related) secretory pathway protein/ Flagellum-specific ATP synthase | 15             | VGAYQQGSDAE <sup>14</sup> LDR | 48                   | Flagellum; Cytoplasm                        | NU                    | 1.97   | 1.241                                |

Legend: \* - UniProt proteome ID UP000014259; &- ORF was not annotated in the re-sequenced Nichols strain genome due to its length below the 150 bp limit<sup>14</sup>; #- underlined/ bold amino acids indicate stable isotope labelled residues; \$- peptide is homologous in Tpr E/G/J protein sequences; @- subcellular location as reported in Osbak *et al.*<sup>16</sup>; NK- not known; NSAF- normalized spectral abundance factor; COG- clusters of orthologous groups; COG categories: L- Replication, recombination and repair; M- Cell wall/membrane/envelope biogenesis; N- Cell motility; O- Posttranslational modification, protein turnover, chaperones; J- Translation, ribosomal structure and biogenesis; S- Function unknown; U- Intracellular trafficking, secretion, and vesicular transport.






**Figure 1. Intensity plots displaying MRM experiments on plasma from an individual with secondary stage syphilis.** (a) synthetic hPTPs, even numbers and (b) endogenous (*T. pallidum*) PTPs, odd numbers; gradient 1 of 3. For each peptide the number of selected transitions (channels) is reported. The x-axis shows the chromatographic retention time of the corresponding peptide while the y-axis shows the relative intensity of the MS2 signal. Note: Signal fluctuations present in the 'endogenous' PTP chromatogram are always the result of just one transition, often coupled with a shift in retention time and differing m/z-values differ from the hPTP run, thus these are considered to be noise.



**Figure 2.** Work-flow diagram describing the estimation of *T. pallidum* protein MS LOD experiments. In total, eight different concentrations of *T. pallidum* (from  $10^4$  to 0 bacteria/ml PBS) were treated in three different ways i) *T. pallidum* was enriched using magnetic beads coated with polyclonal anti-*T. pallidum* antibodies and lysed by sonication for release of *T. pallidum* proteins in the supernatant. Acetone precipitated proteins were trypsinized; ii) In order to detect any remaining protein on the beads, the beads were also trypsinized (retentant on-bead trypsinization); iii) As a control, non-enriched samples were sonicated and immediately trypsinized. \*-proteins selected as candidate biomarkers in this study. All samples were analysed by an LTQ-Orbitrap mass spectrometer.



**Figure 3.** *T. pallidum* proteins detected in LOD magnetic bead coupled polyclonal anti-*T. pallidum* antibody enrichment experiments (protein and peptide identification threshold of 95 %).

concentration calculations estimated that our target PTPs would be present in the femtomoles per liter range in human *T. pallidum* infection (calculations presented in [Supplementary File 4](#)).

## Discussion

The *T. pallidum* MRM assay designed in this study failed to detect any of the 30 targeted proteotypic peptides related to eleven candidate *T. pallidum* protein biomarkers in eighteen plasma and four urine samples from individuals with syphilis. A number of explanations are possible. The foremost is the extremely low predicted concentration of bacterial proteins compared to host proteins. To a large extent our estimates of *T. pallidum* bacterial load in blood are based on molecular studies. In one of the largest studies, Tipple *et al.* found that median copy numbers of Lipoprotein antigen Tp47 (TP\_0574) DNA detectable per milliliter of whole blood was 127, 516 and 70 in primary, secondary and latent syphilis, respectively<sup>12</sup>. Other studies have produced comparable results<sup>46,63,64</sup>, with the exception of a recent study that found a median of  $1.4 \times 10^5$  *T. pallidum*/ml in whole blood from patients with secondary syphilis<sup>65</sup>.

The concentration of *T. pallidum* in blood according to these PCR-based studies is lower compared to our estimated LOD in a shotgun experiment on diluted samples (300 *T. pallidum*/ml) since we would need a 500x higher concentration (same amount of proteins from 300 *T. pallidum* in 1 ml vs. 2  $\mu$ l) to detect the 300 *T. pallidum*/ml (see [Supplementary File 4](#)). Despite this outcome, we were hoping to detect *T. pallidum* proteins in the plasma or urine of some syphilis patients because i) MRM measurements are generally more sensitive than shotgun experiments since scanning times are drastically reduced and ii) the amounts from Tipple *et al.*<sup>12</sup> were averages so we hypothesized that some patients (especially those with secondary syphilis) might have high *T. pallidum* levels detectable by MRM. These results could then motivate us to develop an (immuno)assay, capable of detecting the proteins even at low concentrations.

Little difference in *T. pallidum* abundance has been found between whole blood, plasma or serum<sup>11</sup>. Not much is known about the persistence of *T. pallidum* in the human urinary tract and to our knowledge no studies have quantified *T. pallidum* in the urine of syphilis-infected patients. However, even if *T. pallidum* does not consistently persist in the urinary tract, bacterial proteins present in the blood could be filtered through the glomerulus, ending up in the urine either intact or as peptide fragments, depending on the size of the protein and state of proteolysis<sup>66</sup>.

These considerations suggest that detection of *T. pallidum* proteins in human biofluids may not be possible without additional steps such as front-end immunoaffinity depletion<sup>67</sup>, two-dimensional LC separation<sup>68</sup> and/or selective enrichment of target proteins/peptides (as reviewed by Shi *et al.*<sup>69</sup>). These techniques, or combinations thereof, have allowed the detection of low abundance proteins up to the low- to sub-nanogram/ml level<sup>69,70</sup> in clinical samples. For example, to reduce the wide dynamic range of plasma proteins, multicomponent single-step immunoaffinity depletion of high-abundant (host) proteins can allow up to

a 10-20-fold enrichment of low-abundant proteins due to the depletion of 90–95 % of the total protein mass<sup>67</sup>. However, of particular concern with this approach is the possibility of concomitant removal of low-abundance proteins due to protein binding to the antibodies or high-abundant proteins, as shown in a study that systematically analysed the antibody bound (high-abundant) protein fraction which found that this fraction contained 101 proteins at a high degree of confidence<sup>71</sup>. *T. pallidum* has a high binding affinity for constituents of serum and host cells, including laminin<sup>72</sup>, fibronectin<sup>73,74</sup> and albumin<sup>75</sup>, which may lead to unintentional depletion of targeted proteins if human protein specific immunodepletion would be applied. Furthermore, targeted mass spectrometric immunoassays (MSIA) that use surface-immobilized antibodies to affinity retrieve proteins from biological samples have proven their utility for clinical applications<sup>76–78</sup>. In our study, magnet bead coupled polyclonal anti- *T. pallidum* antibodies failed to significantly detect more *T. pallidum* proteins compared to the unenriched dilution series. Antibody effectivity is dictated by binding affinity; we used commercial antibodies that were to our knowledge not previously characterized as to their binding affinity or targeted proteins. Furthermore, it is unlikely that the polyclonal antibodies would bind a large range of proteins since few (<5 %) *T. pallidum* proteins are immunogenic<sup>15,79</sup>. The fact that *T. pallidum* can remain in ‘plain sight’ without invoking immune defences<sup>80</sup>, together with the very low amount of outer membrane proteins compared to other human pathogens<sup>81</sup>, also suggests that antibody enrichment of whole organisms and/or proteins would probably not be an effective strategy. Peptide-level immunoenrichment, also known as the ‘Stable Isotope Standards and Capture by Anti-Peptide Antibodies’ (SISCAPA) method developed by Anderson *et al.*<sup>82</sup> has shown considerable promise as a high-throughput, automated, highly multiplexed approach for protein biomarker quantification, with MRM application detection limits in the low picogram/ml range of protein concentration in plasma<sup>83</sup>. If a selection of *T. pallidum* peptides could be definitively demonstrated to be present in plasma or urine, then this could be an attractive analytical approach with a strong potential for yielding the detection capabilities and precision needed for clinical applications.

However, apart from the low abundance in plasma or urine, other factors could explain why the *T. pallidum* proteins were not detected in our MRM experiments:

1. The LOD *T. pallidum* spiking experiments were performed in PBS buffer as opposed to a highly complex plasma or urine matrix background.
2. Variations in gene expression and structural components of proteins could also account for the lack of *T. pallidum* protein detection. Fluctuations in gene expression may explain why we did not find TprG, a protein implicated in phase variation which has been shown to be expressed at varying levels during infection due to changes in the number of guanine nucleotide repeats immediately upstream of its transcriptional start site<sup>84</sup>. Heterogeneous *T. pallidum* protein sequence sites<sup>14,16,85</sup> could also confound rigid MRM assay detection parameters. Such heterogeneity has been shown<sup>16</sup> to be present in one candidate

biomarker, TP\_0922, although this variable site was not present in the PTPs incorporated in this MRM assay. Poor proteolytic cleavage can stem from structural features of the protein, different digestion kinetics and post-translational modifications. For example, phosphorylated residues within two amino acids of the point of cleavage can hinder proteolysis<sup>86</sup>. Little is known about the extent of *T. pallidum* protein post-translational modification aside from a study that demonstrated glycosylation of the Flagellar core proteins (FlaBs) as reported by antibody and glycan staining techniques<sup>87</sup>, however, the exact modification sites and extent of modification remain unknown. Other proteomics studies of *L. interrogans* have demonstrated likely roles for protein acetylation and methylation in virulence mechanisms<sup>88,89</sup>.

3. We only tested eleven out of more than a thousand predicted proteins in the *T. pallidum* proteome<sup>56</sup>, a selection largely based on spectral counting<sup>16</sup> as an estimation of protein abundance. We cannot assume, however, that this indirect manner of quantifying *T. pallidum* protein levels in a rabbit testicle model directly recapitulates *T. pallidum* protein expression levels in plasma samples of syphilis-infected patients. One of the reasons for this is that protein expression may vary according to host and disease stage. Antigen detection during latent stage disease will be especially challenging since *T. pallidum* has been shown to sequester itself in protected niches such as eyes, hair follicles and nerves<sup>90</sup>. Other *T. pallidum* proteins may be more suitable diagnostic biomarkers, given that they are reflective of the disease stages studied and that they are consistently present in the biofluids of interest. For example, Lipoprotein Tp47, which could still be identified in the most diluted *T. pallidum* sample (300 *T. pallidum*/ml) in this study, could be an interesting biomarker for future studies.

4. Various technical limitations such as a possible suboptimal chromatographic gradient length, modifiable proteotypic residues and protein degradation secondary to sample processing could have impeded biomarker detection. Other studies have reported chromatographic gradient lengths of 30 minutes or longer<sup>32,33,35,38</sup>, thus implementation of longer gradients could be considered in future studies in order to improve peptide resolution. In this study, chromatographic separations were performed in triple using shorter 10-minute gradients in order to optimize the sample throughput without the loss of MS sensitivity due to overlapping transition windows. Therefore, co-eluting peptides were split over different chromatographic runs since plasma protein availability was not a limiting factor. Oxidizable proteotypic residues, namely cysteine, methionine and tryptophan, can cause artifactual modifications during processing or storage resulting multiple forms of targeted peptides. With this said, the PTP selection process also requires a necessary balance between many different parameters, whereby selection of peptides containing suboptimal amino acid residues can sometimes remain the most favourable option. Ribosomal protein TP\_0250b was only

represented by one PTP, which may have limited detectability, thus future assays could ideally incorporate more than one peptide per protein.

5. Sample processing may have also contributed to protein degradation; therefore prompt analysis of fresh non-frozen biological specimens, if possible, is recommended. Moreover, alternative sample processing procedures, such as the use of molecular weight cut off filters to concentrate urine could improve protein detectability<sup>39</sup>.

6. Lastly, only a limited amount of clinical samples were analysed, especially urine and the study was a single centre study with only MSM participants, therefore it is not generalizable. An improvement for future studies would be the incorporation of isotopically labelled (non-*T. pallidum*) reference standards, which have been shown to improve analytical precision, detect variations in instrument performance and aid in detecting chemical interferences<sup>91</sup>.

Targeted MS approaches are only able to search for a limited amount of pre-selected biomarker candidates. A more comprehensive approach would be to take a step backwards to conduct broader shotgun proteomics in plasma and urine samples of individuals with syphilis. Shotgun approaches identifying *M. tuberculosis* antigens in urine have been previously successful<sup>39,40</sup>. A compelling study from Eyford *et al.* used a 'deep-mining' proteomics approach and were able to detect 254 *Typanosoma brucei rhodesiense* proteins in plasma from African sleeping sickness patients<sup>92</sup>. Quantitative data-independent acquisition modes of MS analysis, including SWATH-MS<sup>93</sup>, are also very promising avenues for clinical applications<sup>94,95</sup>.

## Conclusions

In an effort to identify promising *T. pallidum* diagnostic biomarkers, we designed a scheduled MRM assay incorporating 141 MRM ions pairs correlated to 30 PTPs/ 11 *T. pallidum* proteins. Factors such as the extremely low (femtomoles per liter) predicted *T. pallidum* protein concentration in biofluids, possible variable protein expression according to host/disease stage and potential presence of protein post-translational modifications likely contributed to the lack of signal detection for all candidate biomarkers investigated. Since the proteins targeted in this study were likely buried in the proverbial haystack of plasma proteins, alternative sample preparation and analysis strategies are warranted. With the rapidly progressing innovations of MS applications and technology, we believe clinical proteomics is far from its pinnacle of potential.

## Data availability

The datasets supporting the conclusions of this article are available in the [PeptideAtlas](#)<sup>53</sup> repository, with the identifier [PASS00978](#), in addition to being provided within the article and its [supplementary files](#).

## Consent and ethics approval

The prospective observational cohort study (SeTPAT Clinical-Trials.gov # [NCT02059525](#)) that provided the clinical samples used in this study was approved by the Institutional Review Board of the Institute of Tropical Medicine Antwerp and the Ethics Committee of the University of Antwerp (13/44/426), Belgium. Written informed consent for publication of the participants' anonymized details was obtained from the participants. The *T. pallidum* ssp. *pallidum* DAL-1 strain used in this study was propagated in rabbits at the Veterinary Research Institute in Brno, Czech Republic. The handling of animals in the study was performed in accordance with the current Czech legislation (Animal Protection and Welfare Act No. 246/1992 Coll. of the Government of the Czech Republic). These specific experiments were approved by the Ethics Committee of the Veterinary Research Institute (Permit Number 20–2014).

## Competing interests

No competing interests were disclosed.

## Grant information

This work was supported by a grant from the Flanders Research Foundation, SOFI-B Grant (#757003) to CRK, <http://www.fwo.be/>.

*The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.*

## Acknowledgements

Special thanks to the study participants, in addition to David Šmajš and Michal Strouhal (Masaryk University, Brno, Czech Republic) for providing the purified *T. pallidum* DAL-1 strain used in this study.

## Supplementary materials

**Supplementary File 1.** Table listing of optimized MRM parameters for 30 peptides targeting 11 *T. pallidum* proteins. (Supplementary File 1.xlsx).

[Click here to access the data.](#)

**Supplementary File 2.** Examples of intensity plots.

[Click here to access the data.](#)

**Supplementary File 3.** Table listing of protein and peptide reports for the LOD experiments using purified *T. pallidum* dilution series and ESI-LTQ-Orbitrap MS/MS analysis. (Supplementary File 3.xlsx).

[Click here to access the data.](#)

**Supplementary File 4.** Calculations to estimate concentration of *T. pallidum* proteins corresponding to proteotypic peptides (PTPs) in human syphilis infections. (Supplementary file 4.xlsx).

[Click here to access the data.](#)

## References

- Newman L, Rowley J, Vander Hoorn S, *et al.*: **Global Estimates of the Prevalence and Incidence of Four Curable Sexually Transmitted Infections in 2012 Based on Systematic Review and Global Reporting.** *PLoS One.* 2015; **10**(12): e0143304.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Van de Laar M, Spiteri G: **Increasing trends of gonorrhoea and syphilis and the threat of drug-resistant gonorrhoea in Europe.** *Euro Surveill.* 2012; **17**(29): pii: 20225.  
[PubMed Abstract](#)
- Peterman TA, Su J, Bernstein KT, *et al.*: **Syphilis in the United States: on the rise?** *Expert Rev Anti Infect Ther.* Informa UK, Ltd; 2015; **13**(2): 161–8.  
[PubMed Abstract](#) | [Publisher Full Text](#)
- Kenyon C, Lynen L, Florence E, *et al.*: **Syphilis reinfections pose problems for syphilis diagnosis in Antwerp, Belgium - 1992 to 2012.** *Euro Surveill.* 2014; **19**(45): 20958.  
[PubMed Abstract](#) | [Publisher Full Text](#)
- Ogilvie GS, Taylor DL, Moniruzzaman A, *et al.*: **A population-based study of infectious syphilis rediagnosis in British Columbia, 1995-2005.** *Clin Infect Dis.* 2009; **48**(11): 1554–8.  
[PubMed Abstract](#) | [Publisher Full Text](#)
- Seña AC, White BL, Sparling PF: **Novel *Treponema pallidum* serologic tests: a paradigm shift in syphilis screening for the 21st century.** *Clin Infect Dis.* Oxford University Press; 2010; **51**(6): 700–8.  
[PubMed Abstract](#) | [Publisher Full Text](#)
- Belisle JT, Brandt ME, Radolf JD, *et al.*: **Fatty acids of *Treponema pallidum* and *Borrelia burgdorferi* lipoproteins.** *J Bacteriol.* 1994; **176**(8): 2151–7.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Joyanes P, Borobio M V, Arquez JM, *et al.*: **The association of false-positive**

- rapid plasma reagin results and HIV infection. *Sex Transm Dis.* 1998; **25**(10): 569–71.  
[PubMed Abstract](#) | [Publisher Full Text](#)
9. Monath TP, Frey SE: **Possible autoimmune reactions following smallpox vaccination: the biologic false positive test for syphilis.** *Vaccine.* 2009; **27**(10): 1645–50.  
[PubMed Abstract](#) | [Publisher Full Text](#)
  10. Seña AC, Wolff M, Martin DH, *et al.*: **Predictors of serological cure and Serofast State after treatment in HIV-negative persons with early syphilis.** *Clin Infect Dis.* Oxford University Press; 2011; **53**(11): 1092–9.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
  11. Gayet-Ageron A, Lautenschlager S, Ninet B, *et al.*: **Sensitivity, specificity and likelihood ratios of PCR in the diagnosis of syphilis: a systematic review and meta-analysis.** *Sex Transm Infect.* 2013; **89**(3): 251–6.  
[PubMed Abstract](#) | [Publisher Full Text](#)
  12. Tipple C, Hanna MO, Hill S, *et al.*: **Getting the measure of syphilis: qPCR to better understand early infection.** *Sex Transm Infect.* 2011; **87**(6): 479–85.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
  13. Castro R, Prieto E, Aguas MJ, *et al.*: **Detection of *Treponema pallidum* sp *pallidum* DNA in latent syphilis.** *Int J STD AIDS.* 2007; **18**(12): 842–5.  
[PubMed Abstract](#) | [Publisher Full Text](#)
  14. Pětrošová H, Pospíšilová P, Strouhal M, *et al.*: **Resequencing of *Treponema pallidum* ssp. *pallidum* Strains Nichols and SS14: correction of sequencing errors resulted in increased separation of syphilis treponeme subclusters.** *PLoS One.* 2013; **8**(9): e74319.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
  15. McGill MA, Edmondson DG, Carroll JA, *et al.*: **Characterization and serologic analysis of the *Treponema pallidum* proteome.** *Infect Immun.* 2010; **78**(6): 2631–43.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
  16. Osbak KK, Houston S, Lithgow KV, *et al.*: **Characterizing the Syphilis-Causing *Treponema pallidum* ssp. *pallidum* Proteome Using Complementary Mass Spectrometry.** *PLoS Negl Trop Dis.* 2016; **10**(9): e0004988.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
  17. Smajs D, McKeivitt M, Howell JK, *et al.*: **Transcriptome of *Treponema pallidum*: gene expression profile during experimental rabbit infection.** *J Bacteriol.* American Society for Microbiology; 2005; **187**(5): 1866–74.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
  18. Salazar JC, Rathi A, Michael NL, *et al.*: **Assessment of the kinetics of *Treponema pallidum* dissemination into blood and tissues in experimental syphilis by real-time quantitative PCR.** *Infect Immun.* American Society for Microbiology (ASM); 2007; **75**(6): 2954–8.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
  19. Vaira D, Mallertheiner P, Mégraud F, *et al.*: **Diagnosis of *Helicobacter pylori* infection with a new non-invasive antigen-based assay.** *HpSA European study group.* *Lancet.* 1999; **354**(9172): 30–3.  
[PubMed Abstract](#) | [Publisher Full Text](#)
  20. Jarvis JN, Percival A, Bauman S: **Evaluation of a novel point-of-care cryptococcal antigen test on serum, plasma, and urine from patients with HIV-associated cryptococcal meningitis.** *Clin Infect Dis.* 2011; **53**(10): 1019–23.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
  21. Parisi MT, Tierno PM Jr: **Evaluation of new rapid commercial enzyme immunoassay for detection of *Cryptosporidium* oocysts in untreated stool specimens.** *J Clin Microbiol.* 1995; **33**(7): 1963–5.  
[PubMed Abstract](#) | [Free Full Text](#)
  22. Haque R, Ali IK, Akther S, *et al.*: **Comparison of PCR, isoenzyme analysis, and antigen detection for diagnosis of *Entamoeba histolytica* infection.** *J Clin Microbiol.* 1998; **36**(2): 449–52.  
[PubMed Abstract](#) | [Free Full Text](#)
  23. Cross RW, Boisen ML, Millett MM, *et al.*: **Analytical Validation of the ReEBOV Antigen Rapid Test for Point-of-Care Diagnosis of Ebola Virus Infection.** *J Infect Dis.* 2016; **214** (suppl 3): S210–7.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
  24. Flores LL, Steingart KR, Dendukuri N, *et al.*: **Systematic review and meta-analysis of antigen detection tests for the diagnosis of tuberculosis.** *Clin Vaccine Immunol.* 2011; **18** (10): 1616–27.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
  25. Tramont E, Mandell GL, Bennett JE, *et al.*: **Princ. Pract. Infect. Dis.** 8th ed. Churchill Livingstone Inc. 2015.
  26. Sabbagh B, Mindt S, Neumaier M, *et al.*: **Clinical applications of MS-based protein quantification.** *Proteomics Clin Appl.* 2016; **10**(4): 323–45.  
[PubMed Abstract](#) | [Publisher Full Text](#)
  27. Cheng K, Chui H, Domish L, *et al.*: **Recent development of mass spectrometry and proteomics applications in identification and typing of bacteria.** *Proteomics Clin Appl.* 2016; **10**(4): 346–57.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
  28. Gerber SA, Rush J, Stemman O, *et al.*: **Absolute quantification of proteins and phosphoproteins from cell lysates by tandem MS.** *Proc Natl Acad Sci U S A.* National Academy of Sciences; 2003; **100**(12): 6940–5.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
  29. Kettenbach AN, Rush J, Gerber SA: **Absolute quantification of protein and post-translational modification abundance with stable isotope-labeled synthetic peptides.** *Nat Protoc.* Nature Research; 2011; **6**(2): 175–86.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
  30. Mermelekas G, Vlahou A, Zoidakis J: **SRM/MRM targeted proteomics as a tool for biomarker validation and absolute quantification in human urine.** *Expert Rev Mol Diagn.* 2015; **15**(11): 1441–54.  
[PubMed Abstract](#) | [Publisher Full Text](#)
  31. Pernemalm M, Lehtiö J: **Mass spectrometry-based plasma proteomics: state of the art and future outlook.** *Expert Rev Proteomics.* 2014; **11**(4): 431–48.  
[PubMed Abstract](#) | [Publisher Full Text](#)
  32. Domanski D, Percy AJ, Yang J, *et al.*: **MRM-based multiplexed quantitation of 67 putative cardiovascular disease biomarkers in human plasma.** *Proteomics.* 2012; **12**(8): 1222–43.  
[PubMed Abstract](#) | [Publisher Full Text](#)
  33. Percy AJ, Chambers AG, Yang J, *et al.*: **Multiplexed MRM-based quantitation of candidate cancer biomarker proteins in undepleted and non-enriched human plasma.** *Proteomics.* 2013; **13**(14): 2202–15.  
[PubMed Abstract](#) | [Publisher Full Text](#)
  34. Kuzyk MA, Smith D, Yang J, *et al.*: **Multiple reaction monitoring-based, multiplexed, absolute quantitation of 45 proteins in human plasma.** *Mol Cell Proteomics.* 2009; **8**(8): 1860–77.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
  35. Percy AJ, Yang J, Hardie DB, *et al.*: **Precise quantitation of 136 urinary proteins by LC/MRM-MS using stable isotope labeled peptides as internal standards for biomarker discovery and/or verification studies.** *Methods.* Elsevier Inc.; 2015; **81**: 24–33.  
[PubMed Abstract](#) | [Publisher Full Text](#)
  36. Abeijon C, Kashino SS, Silva FO, *et al.*: **Identification and diagnostic utility of *Leishmania infantum* proteins found in urine samples from patients with visceral leishmaniasis.** *Clin Vaccine Immunol.* 2012; **19**(6): 935–43.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
  37. Abeijon C, Campos-Neto A: **Potential non-invasive urine-based antigen (Protein) detection assay to diagnose active visceral leishmaniasis.** *PLoS Negl Trop Dis.* 2013; **7**(5): e2161.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
  38. Kruh-Garcia NA, Wolfe LM, Chaisson LH, *et al.*: **Detection of *Mycobacterium tuberculosis* peptides in the exosomes of patients with active and latent *M. tuberculosis* infection using MRM-MS.** *Koomen JM, editor. PLoS One.* 2014; **9**(7): e103811.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
  39. Young BL, Mamlaz Z, Gqamana PP, *et al.*: **The identification of tuberculosis biomarkers in human urine samples.** *Eur Respir J.* 2014; **43**(6): 1719–29.  
[PubMed Abstract](#) | [Publisher Full Text](#)
  40. Kashino SS, Pollock N, Napolitano DR, *et al.*: **Identification and characterization of *Mycobacterium tuberculosis* antigens in urine of patients with active pulmonary tuberculosis: an innovative and alternative approach of antigen discovery of useful microbial molecules.** *Clin Exp Immunol.* Wiley-Blackwell; 2008; **153**(1): 56–62.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
  41. Kim SH, Lee NE, Lee JS, *et al.*: **Identification of Mycobacterial Antigens in Human Urine by Use of Immunoglobulin G Isolated from Sera of Patients with Active Pulmonary Tuberculosis.** *Land GA, editor. J Clin Microbiol.* 2016; **54**(6): 1631–7.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
  42. Workowski KA, Berman S; Centers for Disease Control and Prevention (CDC): **Sexually transmitted diseases treatment guidelines, 2010.** *MMWR Recomm Rep.* 2010; **59**(RR-12): 1–110.  
[PubMed Abstract](#)
  43. French P, Gomberg M, Janier M, *et al.*: **IUSTI: 2008 European Guidelines on the Management of Syphilis.** *Int J STD AIDS.* 2009; **20**(5): 300–9.  
[PubMed Abstract](#) | [Publisher Full Text](#)
  44. Liu H, Rodes B, Chen CY, *et al.*: **New tests for syphilis: rational design of a PCR method for detection of *Treponema pallidum* in clinical specimens using unique regions of the DNA polymerase I gene.** *J Clin Microbiol.* 2001; **39**(5): 1941–6.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
  45. Flasarová M, Pospíšilová P, Mikalová L, *et al.*: **Sequencing-based molecular typing of *Treponema pallidum* strains in the Czech Republic: all identified genotypes are related to the sequence of the SS14 strain.** *Acta Derm Venereol.* 2012; **92**(6): 669–74.  
[PubMed Abstract](#) | [Publisher Full Text](#)
  46. Tipple C, Jones R, McClure M, *et al.*: **Rapid *Treponema pallidum* clearance from blood and ulcer samples following single dose benzathine penicillin treatment of early syphilis.** *Vinetz JM, editor. PLoS Negl Trop Dis.* 2015; **9**(2): e0003492.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
  47. Rai AJ, Gelfand CA, Haywood BC, *et al.*: **HUPO Plasma Proteome Project specimen collection and handling: towards the standardization of parameters for plasma proteome samples.** *Proteomics.* 2005; **5**(13): 3262–77.  
[PubMed Abstract](#) | [Publisher Full Text](#)

48. Aguilar-Mahecha A, Kuzyk MA, Domanski D, *et al.*: **The effect of pre-analytical variability on the measurement of MRM-MS-based mid- to high-abundance plasma protein biomarkers and a panel of cytokines.** *Krauss-Etschmann S, editor. PLoS One.* 2012; 7(6):e38290.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
49. Schuchard MD, Mehig RJ, Cockrill SL, *et al.*: **Artifactual isoform profile modification following treatment of human plasma or serum with protease inhibitor, monitored by 2-dimensional electrophoresis and mass spectrometry.** *Biotechniques.* 2005; 39(2): 239–47.  
[PubMed Abstract](#)
50. Human Proteome Organization: **Human Kidney and Urine Proteome Project.** Standard Protocol for Urine Collection and Storage.  
[Reference Source](#)
51. Fusaro VA, Mani DR, Mesirov JP, *et al.*: **Prediction of high-responding peptides for targeted protein assays by mass spectrometry.** *Nat Biotechnol.* 2009; 27(2): 190–8.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
52. Altschul SF, Gish W, Miller W, *et al.*: **Basic local alignment search tool.** *J Mol Biol.* 1990; 215(3): 403–10.  
[PubMed Abstract](#) | [Publisher Full Text](#)
53. Desiere F, Deutsch EW, King NL, *et al.*: **The PeptideAtlas project.** *Nucleic Acids Res. Oxford University Press;* 2006; 34(Database issue): D655–8.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
54. Lukehart SA, Marra CM: **Isolation and laboratory maintenance of *Treponema pallidum*.** *Curr Protoc Microbiol.* 2007; Chapter 12: Unit 12A.1.  
[PubMed Abstract](#) | [Publisher Full Text](#)
55. Hanff PA, Norris SJ, Lovett MA, *et al.*: **Purification of *Treponema pallidum*, Nichols strain, by Percoll density gradient centrifugation.** *Sex Transm Dis.* 1984; 11(4): 275–86.  
[PubMed Abstract](#) | [Publisher Full Text](#)
56. Fraser CM, Norris SJ, Weinstock GM, *et al.*: **Complete genome sequence of *Treponema pallidum*, the syphilis spirochete.** *Science.* American Association for the Advancement of Science. 1998; 281(5375): 375–88.  
[PubMed Abstract](#) | [Publisher Full Text](#)
57. Keller A, Nesvizhskii AI, Kolker E, *et al.*: **Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search.** *Anal Chem.* 2002; 74(20): 5383–92.  
[PubMed Abstract](#) | [Publisher Full Text](#)
58. Desrosiers DC, Anand A, Luthra A, *et al.*: **TP0326, a *Treponema pallidum*  $\beta$ -barrel assembly machinery A (BamA) orthologue and rare outer membrane protein.** *Mol Microbiol.* 2011; 80(6): 1496–515.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
59. Cameron CE, Lukehart SA, Castro C, *et al.*: **Opsonic potential, protective capacity, and sequence conservation of the *Treponema pallidum* subspecies *pallidum* Tp92.** *J Infect Dis.* 2000; 181(4): 1401–13.  
[PubMed Abstract](#) | [Publisher Full Text](#)
60. Luthra A, Anand A, Hawley KL, *et al.*: **A Homology Model Reveals Novel Structural Features and an Immunodominant Surface Loop/Opsonic Target in the *Treponema pallidum* BamA Ortholog TP\_0326.** *J Bacteriol.* 2015; 197(11): 1906–20.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
61. Gayet-Ageron A, Laurent F, Schrenzel J, *et al.*: **Performance of the 47-kilodalton membrane protein versus DNA polymerase I genes for detection of *Treponema pallidum* by PCR in ulcers.** *J Clin Microbiol.* 2015; 53(3): 976–80.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
62. Centurion-Lara A, Giacani L, Godomes C, *et al.*: **Fine analysis of genetic diversity of the *tpr* gene family among treponemal species, subspecies and strains.** *PLoS Negl Trop Dis.* Public Library of Science; 2013; 7(5): e2222.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
63. Zhou L, Gong R, Lu X, *et al.*: **Development of a Multiplex Real-Time PCR Assay for the Detection of *Treponema pallidum*, HCV, HIV-1, and HBV.** *Jpn J Infect Dis.* 2015; 68(6): 481–7.  
[PubMed Abstract](#) | [Publisher Full Text](#)
64. Cruz AR, Pillay A, Zuluaga AV, *et al.*: **Secondary syphilis in cali, Colombia: new concepts in disease pathogenesis.** *PLoS Negl Trop Dis.* Lukehart S, editor. Public Library of Science; 2010; 4(5): e690.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
65. Pinto M, Antelo M, Ferreira R, *et al.*: **A retrospective cross-sectional quantitative molecular approach in biological samples from patients with syphilis.** *Microb Pathog.* 2017; 104: 296–302.  
[PubMed Abstract](#) | [Publisher Full Text](#)
66. Lawn SD: **Point-of-care detection of lipoarabinomannan (LAM) in urine for diagnosis of HIV-associated tuberculosis: a state of the art review.** *BMC Infect Dis.* BioMed Central Ltd; 2012; 12: 103.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
67. Wu C, Duan J, Liu T, *et al.*: **Contributions of immunoaffinity chromatography to deep proteome profiling of human biofluids.** *J Chromatogr B Analyt Technol Biomed Life Sci.* 2016; 1021: 57–68.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
68. Percy AJ, Simon R, Chambers AG, *et al.*: **Enhanced sensitivity and multiplexing with 2D LC/MRM-MS and labeled standards for deeper and more comprehensive protein quantitation.** *J Proteomics.* 2014; 106: 113–24.  
[PubMed Abstract](#) | [Publisher Full Text](#)
69. Shi T, Su D, Liu T, *et al.*: **Advancing the sensitivity of selected reaction monitoring-based targeted quantitative proteomics.** *Proteomics.* 2012; 12(8): 1074–92.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
70. Keshishian H, Addona T, Burgess M, *et al.*: **Quantitative, multiplexed assays for low abundance proteins in plasma by targeted mass spectrometry and stable isotope dilution.** *Mol Cell Proteomics.* 2007; 6(12): 2212–29.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
71. Yadav AK, Bhardwaj G, Basak T, *et al.*: **A systematic analysis of eluted fraction of plasma post immunoaffinity depletion: implications in biomarker discovery.** *PLoS One.* Public Library of Science; 2011; 6(9): e24442.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
72. Cameron CE: **Identification of a *Treponema pallidum* laminin-binding protein.** *Infect Immun.* American Society for Microbiology (ASM); 2003; 71(5): 2525–33.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
73. Cameron CE, Brown EL, Kuroiwa JM, *et al.*: ***Treponema pallidum* fibronectin-binding proteins.** *J Bacteriol.* 2004; 186(20): 7019–22.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
74. Brinkman MB, McGill MA, Pettersson J, *et al.*: **A novel *Treponema pallidum* antigen, TP0136, is an outer membrane protein that binds human fibronectin.** *Infect Immun.* American Society for Microbiology; 2008; 76(5): 1848–57.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
75. Penn CW, Cockayne A, Bailey MJ: **The outer membrane of *Treponema pallidum*: biological significance and biochemical properties.** *J Gen Microbiol.* Microbiology Society; 1985; 131(9): 2349–57.  
[PubMed Abstract](#) | [Publisher Full Text](#)
76. Krastins B, Prakash A, Sarracino DA, *et al.*: **Rapid development of sensitive, high-throughput, quantitative and highly selective mass spectrometric targeted immunoassays for clinically important proteins in human plasma and serum.** *Clin Biochem.* 2013; 46(6): 399–410.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
77. Nelson RW, Krone JR, Bieber AL, *et al.*: **Mass Spectrometric Immunoassay.** *Anal Chem.* American Chemical Society; 1995; 67(7): 1153–8.  
[PubMed Abstract](#) | [Publisher Full Text](#)
78. Madian AG, Rochelle NS, Regnier FE: **Mass-linked immuno-selective assays in targeted proteomics.** *Anal Chem.* American Chemical Society; 2013; 85(2): 737–48.  
[PubMed Abstract](#) | [Publisher Full Text](#)
79. Brinkman MB, Mckevitt M, McLoughlin M, *et al.*: **Reactivity of antibodies from syphilis patients to a protein array representing the *Treponema pallidum* proteome.** *J Clin Microbiol.* American Society for Microbiology; 2006; 44(3): 888–91.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
80. Salazar JC, Hazlett KR, Radolf JD: **The immune response to infection with *Treponema pallidum*, the stealth pathogen.** *Microbes Infect.* 2002; 4(11): 1133–40.  
[PubMed Abstract](#) | [Publisher Full Text](#)
81. Lafond RE, Lukehart SA: **Biological basis for syphilis.** *Clin Microbiol Rev.* 2006; 19(1): 29–49.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
82. Anderson NL, Anderson NG, Haines LR, *et al.*: **Mass spectrometric quantitation of peptides and proteins using Stable Isotope Standards and Capture by Anti-Peptide Antibodies (SISCAPA).** *J Proteome Res.* 2004; 3(2): 235–44.  
[PubMed Abstract](#) | [Publisher Full Text](#)
83. Whiteaker JR, Zhao L, Anderson L, *et al.*: **An automated and multiplexed method for high throughput peptide immunoaffinity enrichment and multiple reaction monitoring mass spectrometry-based quantification of protein biomarkers.** *Mol Cell Proteomics.* American Society for Biochemistry and Molecular Biology; 2010; 9(1): 184–96.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
84. Giacani L, Lukehart S, Centurion-Lara A: **Length of guanosine homopolymeric repeats modulates promoter activity of subfamily II *tpr* genes of *Treponema pallidum* ssp. *pallidum*.** *FEMS Immunol Med Microbiol.* The Oxford University Press; 2007; 51(2): 289–301.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
85. Giacani L, Molini BJ, Kim EY, *et al.*: **Antigenic variation in *Treponema pallidum*: TprK sequence diversity accumulates in response to immune pressure during experimental syphilis.** *J Immunol.* American Association of Immunologists; 2010; 184(7): 3822–9.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
86. Molina H, Horn DM, Tang N, *et al.*: **Global proteomic profiling of**

- phosphopeptides using electron transfer dissociation tandem mass spectrometry.** *Proc Natl Acad Sci U S A.* 2007; **104** (7): 2199–204.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
87. Wyss C: **Flagellins, but not endoflagellar sheath proteins, of *Treponema pallidum* and of pathogen-related oral spirochetes are glycosylated.** *Infect Immun.* 1998; **66**(12): 5751–4.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
88. Eshghi A, Pinne M, Haake DA, *et al.*: **Methylation and *in vivo* expression of the surface-exposed *Leptospira interrogans* outer-membrane protein OmpL32.** *Microbiology.* 2012; **158**(Pt 3): 622–35.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
89. Wittchell TD, Eshghi A, Nally JE, *et al.*: **Post-translational modification of LipL32 during *Leptospira interrogans* infection.** Small PLC, editor. *PLoS Negl Trop Dis.* 2014; **8**(10): e3280.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
90. Sell S, Salman J, Norris SJ: **Reinfection of chancre-immune rabbits with *Treponema pallidum*. I. Light and immunofluorescence studies.** *Am J Pathol.* 1985; **118**(2): 248–55.  
[PubMed Abstract](#) | [Free Full Text](#)
91. Percy AJ, Chambers AG, Smith DS, *et al.*: **Standardized protocols for quality control of MRM-based plasma proteomic workflows.** *J Proteome Res.* American Chemical Society; 2013; **12**(1): 222–33.  
[PubMed Abstract](#) | [Publisher Full Text](#)
92. Eyford BA, Ahmad R, Enyaru JC, *et al.*: **Identification of Trypanosome proteins in plasma from African sleeping sickness patients infected with *T. b. rhodesiense*.** *PLoS One.* 2013; **8**(8): e71463.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
93. Anjo SI, Santa C, Manadas B: **SWATH-MS as a tool for biomarker discovery: From basic research to clinical applications.** *Proteomics.* 2017; **17**(3–4): 1600278.  
[PubMed Abstract](#) | [Publisher Full Text](#)
94. Nigjeh EN, Chen R, Brand RE, *et al.*: **Quantitative Proteomics Based on Optimized Data-Independent Acquisition in Plasma Analysis.** *J Proteome Res.* 2017; **16**(2): 665–76.  
[PubMed Abstract](#) | [Publisher Full Text](#)
95. Gillet LC, Navarro P, Tate S, *et al.*: **Targeted data extraction of the MS/MS spectra generated by data-independent acquisition: a new concept for consistent and accurate proteome analysis.** *Mol Cell Proteomics.* American Society for Biochemistry and Molecular Biology; 2012; **11**(6): O111.016717.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)



# Open Peer Review

Current Referee Status:



Version 1

Referee Report 22 August 2018

<https://doi.org/10.5256/f1000research.15178.r35202>



**Timothy Palzkill**

Department of Pharmacology and Chemical Biology, Baylor College of Medicine, Houston, TX, USA

This paper by Van Raemdonck describes the use of mass spectroscopy to identify *T. pallidum* proteins from plasma and urine from infected patients. If successful, such a method would be very useful in syphilis diagnostics, particularly with regard to reinfection. Thus, the work addresses a significant problem. However, although they could detect isotopically labeled peptides spiked into the samples, they could not detect *T. pallidum* proteins from the infecting organisms. Limit of detection experiments suggest this is due to the very low concentrations of *T. pallidum* proteins in plasma and serum samples. Thus, the main goal produced a negative result. However, there is considerable useful information in this study. The limit of detection experiments with *T. pallidum* bacteria that have been diluted and were unenriched or enriched with antibody beads provided interesting results on which proteins could be detected and how many bacteria per ml were needed for detection. In addition, the MRM experiments appear to be carefully designed and provide important limit of detection information for future studies. The discussion provides a useful assessment of limiting factors in the direct detection of *T. pallidum* antigen proteins.

Comments:

1. Some of the description of LOD experiments with dilutions of *T. pallidum* on page 7, right column, paragraph 2, is difficult to follow. The authors state "In total, eight unique *T. pallidum* proteins were found in the unenriched and enriched retentate..." but they do not state a dilution. Later in the paragraph, it states "Ten unique *T. pallidum* proteins were found in the highest concentration....". This is confusing. What condition does the eight unique proteins refer to?
2. Page 7, right column, paragraph 2. Tp47 is discussed twice in the paragraph with different gene names each time, ie, Tp47 (TP\_0547) and Tp47 (TP\_0574).
3. Page 3, Introduction, paragraph 1, line 1. "*T. pallidum*, a non-culturable..." Suggest updating based on recent publication in mBio on culturing *T. pallidum*.
4. Figure 3. Please indicate the meaning of the asterisks on TP\_0249, etc.

**Is the work clearly and accurately presented and does it cite the current literature?**

Yes

**Is the study design appropriate and is the work technically sound?**

Yes

**Are sufficient details of methods and analysis provided to allow replication by others?**

Yes

**If applicable, is the statistical analysis and its interpretation appropriate?**

Yes

**Are all the source data underlying the results available to ensure full reproducibility?**

Yes

**Are the conclusions drawn adequately supported by the results?**

Yes

**Competing Interests:** No competing interests were disclosed.

**I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.**

Author Response 03 Oct 2018

**Kara Osbak**, ErasmusMC, Belgium

**1. Some of the description of LOD experiments with dilutions of *T. pallidum* on page 7, right column, paragraph 2, is difficult to follow. The authors state “In total, eight unique *T. pallidum* proteins were found in the unenriched and enriched retentate...” but they do not state a dilution. Later in the paragraph, it states “Ten unique *T. pallidum* proteins were found in the highest concentration....” . This is confusing. What condition does the eight unique proteins refer to?**

This ambiguous sentence has now been reworded- “In total, eight unique *T. pallidum* proteins were found in both the unenriched and enriched retentate dilution series in one or more of the concentrations analyzed”. This refers to the proteins that were commonly found in both experiments, regardless of concentration. The details of which are provided in Supplementary Table 3.

The other sentence was also reworded for clarify “Ten unique *T. pallidum* proteins were found in the highest concentration ( $10^4$  bacteria/ml) four in the enriched retentate sample (N = 10) and non-enriched sample (N = 10), two proteins detected were unique to either the enriched or unenriched samples (Figure 3).”

**2. Page 7, right column, paragraph 2. Tp47 is discussed twice in the paragraph with different gene names each time, ie, Tp47 (TP\_0547) and Tp47 (TP\_0574).**

Thanks for pointing this out, this has been rectified to the actual ORF (TP\_0574).

**3. Page 3, Introduction, paragraph 1, line 1. “*T. pallidum*, a non-culturable...” Suggest updating based on recent publication in mBio on culturing *T. pallidum*.**

Good idea, this reference has now been added.

#### 4. Figure 3. Please indicate the meaning of the asterisks on TP\_0249, etc.

The asterisks refer to “\*-proteins selected as candidate biomarkers in this study.”. This information has now been added

**Competing Interests:** None

Referee Report 27 July 2018

<https://doi.org/10.5256/f1000research.15178.r35906>



**Mohd M. Khan**

University of Maryland, Baltimore, MD, USA

The article “Needle lost in the haystack: multiple reaction monitoring fails to detect *Treponema pallidum* candidate protein biomarkers in plasma and urine samples from individuals with syphilis” focuses on developing targeted proteomics based assay to detect and validate potential biomarkers of *Treponema pallidum* infection. The manuscript is well written, the rationale behind the work is justified, and the methods section is detailed.

I would suggest few points as following:

- Please add the details about participant consent and study approval by the Institutional Review Board (IRB).
- Why only 4 urine samples were analyzed? Which protein marker(s) supposedly should be detected in urine? And which one(s) in plasma? Please consider adding the details and rationale.
- Authors have used microflow for the experiments on quadrupole, which has lower sensitivity. Perhaps targeted experiments using a nanoflow setup, as was done for experiments using orbitrap, will get better sensitivity.
- The synthetic peptides were added after SPE clean-up. Why weren't they added before SPE to determine losses?
- Please supply more information on how LOD was calculated; it was based on the dilution series? The readers can use the explanation of calculations, if provided.
- The spiking experiments should have been done in real matrix?
  - Please comment more on PTP selection? Are they unique? What about labile residues? Was anything done to look at the methionine oxidation? Deamidations? etc.
- The synthetic peptides were 95% pure. Were they quantified? (AAA?)

The paper makes an interesting list of its shortcomings in the discussion, which is helpful. A lot of the critique is already self-proclaimed. The overall conclusion of manuscript is: "A lot of effort and fine-tuning of sample prep/method development will be needed for biomarker discovery and validation." Biomarker validation is time-consuming and challenging, perhaps some orthogonal experiments should have been done (such as western blotting) to be able to know if the global data acquired using spectral-count was good enough before moving on to the MRM experiments. Nonetheless, authors have done a great job in discussing the shortcomings and in writing the paper.

**Is the work clearly and accurately presented and does it cite the current literature?**

Yes

**Is the study design appropriate and is the work technically sound?**

Yes

**Are sufficient details of methods and analysis provided to allow replication by others?**

Yes

**If applicable, is the statistical analysis and its interpretation appropriate?**

Yes

**Are all the source data underlying the results available to ensure full reproducibility?**

Yes

**Are the conclusions drawn adequately supported by the results?**

Yes

**Competing Interests:** No competing interests were disclosed.

**Referee Expertise:** Mass Spectrometry based Proteomics, Secretomics, and Phosphoproteomics

**I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.**

Author Response 03 Oct 2018

**Kara Osbak**, ErasmusMC, Belgium

**Please add the details about participant consent and study approval by the Institutional Review Board (IRB).**

The following information is available under the section "Consent and Ethics Approval": "*The prospective observational cohort study (SeTPAT ClinicalTrials.gov # [NCT02059525](#)) that provided the clinical samples used in this study was approved by the Institutional Review Board of the Institute of Tropical Medicine Antwerp and the Ethics Committee of the University of Antwerp (13/44/426), Belgium. Written informed consent for publication of the participants' anonymized details was obtained from the participants.*"

**Why only 4 urine samples were analyzed? which protein marker(s) supposedly should be detected in urine? and which one(s) in plasma? please consider adding the details and rationale.**

As this was an exploratory biomarker study we did not stratify our biomarker selection by biofluid type, thus the potential biomarkers mentioned in this study were theoretically applicable to urine and blood. No previous studies of this type have been performed, hence our selection, as described, was based on our shotgun proteomics studies of *Treponema pallidum* during rabbit infection, literature inferences on previous microarray studies and physiochemical characteristics that would be amendable to MRM detection.

Admittedly, only analyzing four urine samples is a small number. It became apparent that our experimental strategy was not working after analyzing the initial set of samples that we decided not to go further. Despite this small number, we believe this information might be useful for other

groups considering employing similar methods.

**Authors have used microflow for the experiments on quadrupole, which has lower sensitivity. Perhaps targeted experiments using a nanoflow setup, as was done for experiments using orbitrap, will get better sensitivity.**

Indeed, one would expect higher sensitivity with the nanoflow set-up, however, to analyze larger volumes of patient material, which might also increase the sensitivity, the microflow set-up is more advantageous. Moreover, targeted microflow LC-MS/MS experiments offer the benefit of increased throughput (the initial goal was to develop method to analyze larger sample cohorts in a short time) and robustness.

**The synthetic peptides were added after SPE clean-up. Why weren't they added before SPE to determine losses?**

In this exploratory study, multiple candidate biomarkers were included in the targeted setup to evaluate their potency. Therefore, it was not yet clear in which final concentration these synthetic peptides should be spiked into the samples. At this stage of the study, the synthetic peptides were also not exactly quantified (i.e. AQUA Basic peptides), which would make the determination of losses during sample preparation not precise.

**Please supply more information on how LOD was calculated; it was based on the dilution series? The readers can use the explanation of calculations, if provided.**

The LOD calculations were based on the dilution series of *T. pallidum* in PBS, which were either enriched or unenriched with magnetic beads coupled with polyclonal antibodies directed against *T. pallidum*. These were then subjected to LTQ Orbitrap analyses. Two unique *T. pallidum* proteins, Cytoplasmic filament protein A (TP\_0748) and Lipoprotein antigen Tp47 (TP\_0547), were found in the 300 bacteria/ml fraction in the enriched and unenriched samples, respectively. Therefore, the LOD based on a high-resolution LTQ-Orbitrap instrument was approximately 300 bacteria/ml PBS for both the antibody enriched and unenriched samples, meaning there was no significant improvement in LOD using bead enrichment. These results are detailed in Supplementary File 3. Furthermore, rough concentration calculations based on previous studies were presented in Supplementary Table 4 which estimated that the concentration of *T. pallidum*/ target PTPs in human serum would be in the femtomoles per liter range during human *T. pallidum* infection (calculations presented in Supplementary File 4).

**The spiking experiments should have been done in real matrix?**

Indeed, the final dilution series of the labeled synthetic peptides, that would be used to determine the absolute concentration of the candidate biomarkers, would have been done in real matrix. However, at this point of the study the goal was to evaluate the abundance of the selected proteotypic peptides before using absolutely quantified labeled peptides (e.g. AQUA Ultimate). Therefore, it was decided to tune and optimize the LC-MS/MS parameters of each labeled peptide without any matrix to determine the most optimal instrument settings.

**Please comment more on PTP selection? Are they unique? What about labile residues? Was anything done to look at the methionine oxidation? deamidations? etc**

Due to the lack of available MS datasets about the *Treponema pallidum* proteome (no library available), proteotypic peptides of each candidate protein biomarker were predicted *in silico*. As described, ESP predictor (Fusaro et al, 2009 Nat. Biotechnology) was used to find the most suitable proteotypic peptides based on 550 physico-chemical parameters including potential modifications (e.g. oxidation of methionine, deamidation, phosphorylation etc.). Best scoring

peptides were selected for each of the proteins. Moreover, the PTPs that were selected were subjected to BLAST analyses to confirm their uniqueness.

**The synthetic peptides were 95% pure. Were they quantified? (AAA?)**

During this exploratory study AQUA Basic peptides (Thermo Fisher Scientific) were used to evaluate the abundance of the selected proteotypic peptides. Although the quantity of the PTPs were specified in the leaflet, the peptides were purchased in a lyophilized formulation as one aliquot. Therefore, they are not suited as reference for absolute quantification. In a next step, AQUA Ultimate peptides (with a high concentration precision) would have been used to determine the absolute abundance of the protein biomarkers.

***Competing Interests:*** None

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact [research@f1000.com](mailto:research@f1000.com)

**F1000Research**